Peptide Research • Sleep & Neurobiology

DSIP (Emideltide) Reconstitution & BAC Water Guide

DSIP, also called delta-sleep-inducing peptide or emideltide, is a synthetic nonapeptide that has been investigated in sleep, neurobiology and other experimental areas. Historical human studies used intravenous administration, but current FDA evaluation found the clinical evidence limited and did not identify evidence supporting the proposed subcutaneous route.

There is no scientifically established universal BAC-water volume for DSIP. The resulting concentration is determined mathematically from the amount of peptide and the final liquid volume.

Research / Investigational Nonapeptide No FDA-approved DSIP product
Simplified DSIP peptide research illustration Scientific illustration representing DSIP or emideltide as a short peptide chain alongside sleep-wave and neuroscience symbols. Trp Ala Gly Gly Asp Ala DSIP / EMIDELTIDE Delta-sleep-inducing peptide research
Conceptual DSIP peptide and sleep-wave illustration.

Research Snapshot

Compound
DSIP / Emideltide
Class
Synthetic nonapeptide
Research Category
Sleep & neurobiology
Regulatory Status
Investigational / not FDA-approved
Human Evidence
Limited and inconsistent
Vial Quantities
No standardized commercial quantity established by the authoritative sources reviewed
Last Reviewed
September 10, 2026

How Much BAC Water for DSIP / Emideltide?

There is no single scientifically established BAC-water volume for DSIP / emideltide.

The correct mathematical concentration depends on two variables: the total amount of peptide in the vial and the final liquid volume. Increasing the liquid volume lowers the concentration; decreasing the volume increases it.

These calculations should not be confused with a clinical dose, a manufacturer-specific reconstitution instruction, an FDA-approved dosage, or a community protocol.

Illustrative DSIP Concentration Examples

Vial Quantity 1 mL 2 mL 2.5 mL 3 mL 5 mL
5 mg 5 mg/mL 2.5 mg/mL 2 mg/mL 1.67 mg/mL 1 mg/mL
10 mg 10 mg/mL 5 mg/mL 4 mg/mL 3.33 mg/mL 2 mg/mL
Important: 5 mg and 10 mg are used here as mathematical examples only. They are not presented as verified standardized DSIP commercial vial sizes.

How Much BAC Water Should Be Added to 5 mg or 10 mg of DSIP?

Neither 5 mg nor 10 mg of DSIP has a universally established BAC-water volume in authoritative sources reviewed for this page. Instead, the liquid volume determines the resulting concentration.

How Much BAC Water for 5 mg DSIP?

Mathematically, 5 mg divided by 1 mL produces 5 mg/mL, while 5 mg divided by 5 mL produces 1 mg/mL.

Other volumes produce proportional concentrations. The appropriate experimental concentration should come from the protocol or validated product documentation being used, rather than from a universal internet protocol.

How Much BAC Water for 10 mg DSIP?

A 10 mg quantity divided by 1 mL produces 10 mg/mL. Dividing the same 10 mg quantity by 2 mL produces 5 mg/mL.

These are mathematical concentration outcomes only and do not establish an appropriate human dose or route of administration.

Research schematic

DSIP, Sleep Research & Neurobiology

DSIP was originally investigated as a candidate sleep-related peptide. Research has examined effects on sleep architecture, EEG activity, circadian patterns and other neurophysiological endpoints.

However, the relationship between DSIP and normal human sleep regulation remains unresolved. A 2006 review described the sleep-factor hypothesis as weakly supported and noted uncertainty surrounding DSIP's biological role.

Simplified DSIP sleep research schematic Conceptual diagram showing DSIP research connected with brain signaling, EEG activity, sleep architecture and circadian research. CNS / SLEEP RESEARCH EEG / DELTA sleep-wave research SLEEP ARCHITECTURE duration / stages CIRCADIAN SIGNALS experimental research Simplified research schematic — not a molecular pathway

What Is DSIP / Emideltide?

Delta-sleep-inducing peptide (DSIP), also called emideltide, is a synthetic nonapeptide. FDA's 2026 review identifies emideltide free base as Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and reports a molecular weight of approximately 848.814 g/mol for the free base.

DSIP was historically investigated as a potential endogenous sleep-related factor. Early research reported effects on sleep and electrophysiological activity, but subsequent reviews have emphasized uncertainty about its physiological role and mechanism.

Terminology matters

FDA's current review distinguishes emideltide free base and emideltide acetate. These are distinct bulk drug substances, and the FDA review notes that historical literature does not always clearly identify which form was studied.

How Has DSIP Been Studied?

Unlike compounds with a well-established receptor-mediated mechanism, DSIP's precise biological mechanism remains incompletely established. FDA's 2026 review summarized animal and experimental evidence suggesting effects on sleep-related EEG activity and possible modulation of endogenous opioid signaling.

Animal research

EEG activity

Studies in rabbits, cats and rats reported changes in delta-wave and spindle activity associated with non-REM sleep.

Mechanistic research

Enkephalin signaling

Experimental work reviewed by FDA suggests DSIP may facilitate enkephalin release through a calcium-dependent mechanism rather than directly binding opioid receptors.

Human research

Sleep endpoints

Small human studies have investigated sleep latency, sleep efficiency, awakenings and total sleep time.

What Is DSIP Being Studied For?

Sleep Research

Historical DSIP research focused heavily on sleep, including sleep architecture, sleep efficiency, sleep latency and EEG activity. However, the evidence is old, heterogeneous and limited by small studies.

Neurobiology

DSIP has also been investigated in relation to neurophysiological signaling, neurotransmitter systems and experimental behavioral effects.

Opioid Withdrawal Research

Historical clinical studies investigated DSIP during opioid and alcohol withdrawal. FDA's review concluded that the available evidence was insufficient to establish effectiveness.

Narcolepsy Research

FDA identified a single-patient case report involving narcolepsy, but concluded that the evidence was insufficient to support effectiveness.

Human Clinical Research

Human research on DSIP exists, but it is limited and predominantly historical. Several early studies used intravenous administration and small sample sizes. FDA's 2026 review found that these studies do not establish effectiveness for the proposed subcutaneous route.

Evidence-level distinction

No clinically established human dose has been identified for DSIP / emideltide. Published doses should therefore be understood as historical experimental research parameters, not current treatment recommendations.

Doses Studied in Published Research

The following examples summarize doses reported in historical human research and FDA's 2026 evidence review. They are provided for scientific context only.

These are NOT BacScience dosage recommendations.

A research dose, concentration, route and reconstitution volume are separate concepts. Historical intravenous research cannot be converted into a recommended subcutaneous protocol.

Study Population Dose Studied Route Frequency Duration Key Finding
Schneider-Helmert et al., 1981 Healthy volunteers 25 nmol/kg IV infusion Experimental administration Acute Reported sleep-related effects in a small double-blind crossover study.
Schneider-Helmert & Schoenenberger, 1981 Chronic insomnia 25 nmol/kg IV Single experimental administration Acute Reported changes in sleep duration and sleep quality; study involved only six patients.
Monti et al., 1987 Chronic insomnia 25 nmol/kg IV Repeated experimental administration Four nights Some sleep measures changed, but differences were not consistently significant against baseline/placebo.
Dick et al., 1984 Alcohol or opioid withdrawal 25 nmol/kg IV Up to 6 injections/day in study protocol Up to 6 days Open-label study reported improvement, but methodological limitations substantially limit interpretation.
Backmund et al., 1998 Opioid dependence 35 nmol/kg IV Fixed schedule 7 days Small open-label study; FDA described the evidence as insufficient to establish effectiveness.

Preclinical Research

Animal research has reported effects of emideltide on EEG delta-wave activity, spindle activity and sleep duration in several species. Experimental studies have also investigated analgesic and anticonvulsant effects.

FDA's review also summarized evidence suggesting that DSIP may influence endogenous opioid signaling and reported that experimental studies found DSIP could cross the blood-brain and blood-CSF barriers.

Preclinical evidence is not clinical proof

Findings in animals or isolated experimental systems cannot establish human effectiveness, safety, an appropriate dose, or a suitable reconstitution procedure.

DSIP Research Reconstitution & Concentration

For a simple concentration calculation, divide the total peptide quantity by the liquid volume.

Concentration = Total Vial Quantity ÷ Liquid Volume

Worked Mathematical Examples

Example: 5 mg

5 mg ÷ 1 mL = 5 mg/mL

5 mg ÷ 2 mL = 2.5 mg/mL

5 mg ÷ 5 mL = 1 mg/mL

Example: 10 mg

10 mg ÷ 1 mL = 10 mg/mL

10 mg ÷ 2 mL = 5 mg/mL

10 mg ÷ 5 mL = 2 mg/mL

Mathematical calculation ≠ protocol

The formula tells you the resulting concentration. It does not tell you whether that concentration, diluent, route, dose or storage condition is scientifically appropriate for a particular experiment or product.

BAC Water Volume vs. DSIP Concentration

Less liquid

Higher concentration

Holding the peptide quantity constant, reducing liquid volume increases the calculated concentration.

More liquid

Lower concentration

Adding more liquid increases the volume and therefore lowers the calculated concentration.

Important

Total peptide unchanged

Changing the liquid volume does not change the total mass of peptide represented by the vial.

Is BAC water automatically appropriate for DSIP?

Not necessarily. The authoritative sources reviewed for this page do not establish a universal BAC-water reconstitution protocol for emideltide. Product-specific documentation and validated research methods should take precedence over generic peptide protocols.

Research Limitations, Safety & Regulatory Status

FDA's July 2026 evaluation found that neither emideltide free base nor emideltide acetate has an applicable USP/NF drug-substance monograph and neither is a component of an FDA-approved drug.

FDA also identified concerns involving incomplete characterization, peptide-related impurities, aggregation, limited information on microbial bioburden and bacterial endotoxins, and potential immunogenicity associated with an injectable formulation.

Current FDA evaluation

FDA proposed that both emideltide free base and emideltide acetate not be included on the Section 503A Bulks List. At the July 24, 2026 Pharmacy Compounding Advisory Committee meeting, both forms also received an advisory vote against inclusion: 6 yes, 7 no, 1 abstention.

An advisory-committee vote is not the same thing as FDA drug approval or a final FDA rulemaking decision.

Proposed 1 mg/mL formulation — important distinction

FDA's briefing document describes proposed subcutaneous emideltide products at 1,000 mcg/mL (1 mg/mL). This was part of FDA's evaluation of a proposed compounded product; it was not an FDA-approved DSIP concentration and is not a universal reconstitution instruction.

What Are the Main DSIP Research Limitations?

  • Human studies are generally small and historically concentrated.
  • Many studies used intravenous administration rather than the proposed subcutaneous route.
  • Results across insomnia studies have been inconsistent.
  • Study designs, treatment schedules and endpoints vary considerably.
  • Historical literature does not always distinguish emideltide free base from emideltide acetate.
  • FDA identified characterization, aggregation, impurity and immunogenicity concerns.
  • No clinically established human dose has been identified.

Frequently Asked Questions About DSIP / Emideltide

How much BAC water should be added to DSIP?
There is no universal scientifically established BAC-water volume for DSIP. The resulting concentration depends on the total peptide quantity and liquid volume, so the correct mathematical relationship is concentration = quantity ÷ volume.
How much BAC water for 5 mg DSIP?
There is no universal recommended volume. Mathematically, 5 mg in 1 mL is 5 mg/mL, 5 mg in 2 mL is 2.5 mg/mL, and 5 mg in 5 mL is 1 mg/mL. These are concentration calculations, not dosing advice.
How much BAC water for 10 mg DSIP?
As mathematical examples, 10 mg in 1 mL equals 10 mg/mL, 10 mg in 2 mL equals 5 mg/mL, and 10 mg in 5 mL equals 2 mg/mL.
What is DSIP or emideltide?
DSIP, or delta-sleep-inducing peptide, is also called emideltide. FDA describes it as a synthetic nonapeptide.
Is DSIP FDA approved?
No FDA-approved DSIP drug product was identified in the authoritative sources reviewed. FDA's 2026 evaluation states that emideltide free base and emideltide acetate are not components of an FDA-approved drug.
Is emideltide the same as DSIP?
Yes. FDA uses emideltide as the name for delta-sleep-inducing peptide, or DSIP. However, the specific chemical form matters: FDA separately evaluated emideltide free base and emideltide acetate.
What concentration formula is used for DSIP?
Concentration equals total vial quantity divided by liquid volume. For example, 10 mg divided by 2 mL equals 5 mg/mL.
Does adding more BAC water lower DSIP concentration?
Yes. If the total peptide quantity remains constant, increasing liquid volume lowers the calculated concentration.
Is 1 mg/mL an FDA-recommended DSIP concentration?
No. FDA's 2026 briefing document identified 1 mg/mL as the proposed concentration of a nominated compounded subcutaneous product. It was not an FDA-approved or universal DSIP concentration.
What doses of DSIP have been studied in humans?
Historical studies include intravenous doses such as 25 nmol/kg and 35 nmol/kg. These were experimental research parameters and should not be interpreted as current clinical dosing recommendations.
Does BacScience recommend a human DSIP dose?
No. BacScience does not establish or recommend human dosing. This page provides scientific information and mathematical concentration examples only.
Can an historical IV DSIP dose be converted into a subcutaneous protocol?
No. Route, pharmacokinetics, formulation, concentration and dose are separate variables. FDA specifically concluded that the available evidence did not support the proposed subcutaneous route.

Explore BacScience Research Resources

BAC Water Calculator Calculate concentration from custom vial quantities and liquid volumes. Research Compound Library Replace this placeholder with the live internal library URL. Peptide Research Library Replace this placeholder with the live peptide research library. Testing & Transparency Replace this placeholder with the live testing and transparency resource.

Scientific References

  1. U.S. Food & Drug Administration — Pharmacy Compounding Advisory Committee, July 24, 2026. FDA evaluation of Emideltide (free base) and Emideltide acetate, including characterization, clinical evidence, safety and proposed 503A status.
    FDA briefing document
  2. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neuroscience & Biobehavioral Reviews. 1984. PMID: 6145137.
    PubMed
  3. Graf MV, Kastin AJ. Delta-sleep-inducing peptide: an update. Peptides. 1986. PMID: 3550726.
    PubMed
  4. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide: a still unresolved riddle. Journal of Neurochemistry. 2006. PMID: 16539679.
    PubMed
  5. Schneider-Helmert D, et al. Acute and delayed effects of DSIP on human sleep behavior. 1981. PMID: 6895513.
    PubMed
  6. Monti JM, et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. 1987. PMID: 3583493.
    PubMed
  7. Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man. Neuropsychobiology. 1983. PMID: 6689058.
    PubMed
  8. FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current FDA compounding safety information for emideltide.
    FDA
Last Scientifically Reviewed
September 10, 2026
Research basis
FDA regulatory materials + PubMed-indexed literature
Content status
Educational / research information
Research information only

This page is intended for scientific and educational research purposes. It does not provide medical diagnosis, treatment, prescribing, injection instructions, or individualized dosing advice. Mathematical concentration calculations should not be interpreted as evidence that a particular concentration, diluent, route or dose is appropriate for human use.